Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States
- PMID: 34480812
- PMCID: PMC8663793
- DOI: 10.1111/hae.14403
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States
Abstract
Introduction: Females may have haemophilia with the same factor VIII (FVIII) or factor IX (FIX) levels as affected males. Characterization of females with haemophilia would be useful for health care planning to meet their unique needs. Federally-funded haemophilia treatment centres (HTCs) in the United States contribute data on all individuals with bleeding disorders receiving care to the Population Profile (HTC PP) component of the Community Counts Public Health Surveillance of Bleeding Disorders project.
Aims: To estimate the number of females with haemophilia receiving care at HTCs in the United States and compare their characteristics with those of males with haemophilia.
Methods: HTC PP data collected on people receiving care at an HTC from January 2012 through September 2020 with haemophilia A and B were evaluated by sex for demographic and clinical characteristics.
Results: A factor level < 40% was reported for 23,196 males (97.8%) and 1667 females (47.6%) attending HTCs; 51 (.48%) severe, 79 (1.4%) moderate, and 1537 (17.9%) mild haemophilia patients were female. Females were older, more often White, and less often non-Hispanic than males. Females were less likely to have history of HIV or HCV infection, even among those with severe disease, but twice as likely to have infection status unknown. Females with mild haemophilia were more often uninsured than males.
Conclusions: Females with severe or moderate haemophilia are uncommon, even in specialized care centres; however, almost one in five patients with mild haemophilia was female, indicating needs for specialized care based on factor level and history for affected females.
Keywords: factor IX; factor VIII; haemophilia A; haemophilia B.
© 2021 John Wiley & Sons Ltd. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Conflict of interest statement
DISCLOSURES
CHM, JMS, and ABP designed the study, conducted the research, analyzed the data and wrote the paper. VRB, RFS, TWB, and CJB conducted the research and wrote the paper. RLS has participated as a paid consultant to Bayer, Biomarin, uniQure, Spark, Novo Nordisk, Genentech/Roche, Octapharma, Takeda, Catalyst, Guardian Therapeutics, Pfizer, Hema Biologics, and Sanofi/Sobi and has investigator initiated grants from Octapharma, Genetech, Grifols, and Takeda. TWB has acted as a paid consultant to BioMarin, Tremeau Pharmaceuticals, and uniQure and has participated in advisory boards with Takeda, Pfizer, CSL Behring, Genentech/Roche, Spark, Novo Nordisk, Spark, and Bayer. All other authors stated that they had no interests which might be perceived as posing a conflict or bias.
Figures
References
-
- DiMichele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A. Severe and moderate haemophilia A and B in US females. Haemophilia. 2014;20:e136–e143. - PubMed
-
- National Center on Birth Defects and Developmental Disabilities. Centers for Disease Control and Prevention. HTC Population Profile Technical Notes. 2020. https://www.cdc.gov/ncbddd/hemophilia/communitycounts/data-reports/2020-....
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources